Immutep 2024 Corporate Presentation - LAG-3 Pipeline

Immutep Limited presents its LAG-3 immunotherapy pipeline focused on oncology and autoimmune diseases as of September 2024. The presentation outlines multiple clinical-stage programs including eftilagimod alfa across various cancer indications and collaboration efforts with major pharmaceutical partners. The company is advancing therapies designed to unlock the immune system to fight cancer and autoimmune conditions.